Animal Model Market Size to Worth USD 5.72 Billion by 2033

The global animal model market size is expected to increase USD 5.72 billion by 2033 from USD 2.48 billion in 2023 with a CAGR of 8.71% between 2024 and 2033.

The animal model market encompasses a diverse array of research organisms used to study biological processes, disease mechanisms, and therapeutic interventions. These models serve as invaluable tools in biomedical research, providing insights into human biology and enabling the development of novel treatments and therapies. The demand for animal models is driven by various factors, including the need for better understanding of complex diseases, the pursuit of personalized medicine, and advancements in genetic engineering technologies. In this comprehensive analysis, we delve into the growth drivers, key factors influencing market dynamics, potential restraints, opportunities for expansion, and the competitive landscape within the animal model market.

Animal Model Market Size 2024 to 2033

Key Points

  • North America led the market with the largest market share of 50% in 2023.
  • By application type, the cancer segment has held the largest market share of 44% in 2023.
  • By animal type, the mice & rat segment held the largest share of 53% in 2023.
  • By end use, in 2023, the pharmaceutical & biotechnology companies segment has captured more than 40% of market share in 2023.

Get a Sample:

Growth Factors

Several factors contribute to the growth of the animal model market. One significant driver is the increasing prevalence of chronic and infectious diseases worldwide. As the global burden of diseases such as cancer, cardiovascular disorders, and neurological conditions continues to rise, there is a growing demand for animal models that accurately mimic these diseases’ pathology and progression. Additionally, advancements in genetic engineering techniques, such as CRISPR-Cas9 technology, have revolutionized the field of animal modeling, enabling the creation of genetically modified organisms with enhanced precision and efficiency. These genetically engineered models offer researchers unprecedented opportunities to study the genetic basis of diseases and develop targeted therapies.

Moreover, the emergence of personalized medicine has fueled demand for animal models that can recapitulate the genetic diversity observed in human populations. By utilizing patient-derived xenograft models and genetically diverse animal strains, researchers can tailor experimental approaches to individual patients’ genetic backgrounds, facilitating the development of personalized treatment strategies. Furthermore, the expansion of preclinical research activities in pharmaceutical and biotechnology companies, coupled with increased investments in translational research, has bolstered the demand for animal models for drug discovery and development. These factors collectively contribute to the sustained growth of the animal model market.

Animal Model Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 8.71%
Global Market Size in 2023 USD 2.48 Billion
Global Market Size by 2033 USD 5.72 Billion
U.S. Market Size in 2023 USD 0.93 Billion
U.S. Market Size by 2033 USD 2.15 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Application, By Animal Type, and By End-use
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Animal Model Market Dynamics


Several key drivers propel the growth of the animal model market. One such driver is the growing adoption of animal models in basic research and preclinical studies. Animal models offer researchers a physiological context in which to study complex biological processes, allowing for the investigation of disease mechanisms, drug efficacy, and safety profiles in vivo. Additionally, the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, underscores the importance of animal models in understanding disease pathology and developing effective treatments.

Furthermore, advancements in genetic engineering technologies have expanded the repertoire of available animal models, enabling the creation of genetically modified organisms with precise alterations to their genomes. This has facilitated the development of disease models that more accurately recapitulate human conditions, as well as the generation of humanized animal models for studying immune responses and infectious diseases. The versatility and utility of these genetically engineered models drive their widespread adoption across academic, pharmaceutical, and biotechnology research settings.

Moreover, the rise of collaborative research initiatives and consortia focused on leveraging animal models for translational research has propelled market growth. These partnerships facilitate knowledge sharing, resource pooling, and access to specialized expertise, accelerating the development of innovative therapies and treatment strategies. Additionally, increasing investments in biomedical research infrastructure and facilities, particularly in emerging markets, are driving market expansion by enabling researchers to conduct more sophisticated and comprehensive studies using animal models.


Despite the numerous growth drivers, the animal model market faces several restraints that may hinder its expansion. One significant restraint is ethical concerns surrounding the use of animals in research. Animal welfare considerations, including the ethical treatment and humane care of research animals, have become increasingly prominent, leading to heightened regulatory scrutiny and public scrutiny of animal research practices. This has resulted in stricter regulations governing the use of animal models in research, which can pose logistical and financial challenges for researchers and organizations involved in animal research.

Additionally, the complexity and heterogeneity of human diseases pose challenges for animal modeling efforts. While animal models provide valuable insights into disease mechanisms and therapeutic interventions, they may not always accurately recapitulate the complexity of human biology and disease pathology. Variability in genetic backgrounds, environmental factors, and disease manifestations among different animal models and human patients can limit the translational relevance of preclinical findings, potentially leading to discrepancies between animal studies and clinical outcomes.

Furthermore, the high costs associated with the development and maintenance of animal models, particularly genetically engineered models, can pose a significant financial barrier for researchers and institutions. The expense of acquiring specialized equipment, maintaining animal colonies, and conducting preclinical studies using animal models can strain research budgets, especially in academic and non-profit settings with limited funding resources. These financial constraints may impede access to cutting-edge animal models and hinder research progress in certain areas.


Despite the challenges and restraints, the animal model market presents significant opportunities for growth and innovation. One such opportunity lies in the development of novel animal models that better recapitulate human diseases and biological processes. Advancements in genome editing technologies, such as base editing and prime editing, hold promise for creating more precise and sophisticated animal models with enhanced translational relevance. By leveraging these technologies, researchers can generate animal models with targeted genetic modifications that more closely mimic human disease phenotypes, enabling more accurate preclinical evaluation of therapeutic interventions.

Moreover, the increasing emphasis on translational research and precision medicine opens up opportunities for the development of personalized animal models tailored to individual patients’ genetic backgrounds and disease profiles. Patient-derived xenograft models and patient-specific induced pluripotent stem cell (iPSC) models offer researchers powerful tools for studying disease pathogenesis and drug responses in a patient-specific context, facilitating the development of personalized treatment strategies. Additionally, the integration of multi-omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, holds promise for advancing our understanding of disease mechanisms and identifying novel therapeutic targets using animal models.

Furthermore, the growing trend towards collaborative research partnerships and consortiums presents opportunities for knowledge sharing, resource pooling, and interdisciplinary collaboration in animal modeling research. By fostering collaboration among academic institutions, pharmaceutical companies, contract research organizations (CROs), and government agencies, these initiatives can accelerate the translation of preclinical findings into clinical applications and drive innovation in the field of animal modeling. Additionally, increasing investments in research infrastructure and facilities, particularly in emerging markets, can expand access to state-of-the-art animal modeling technologies and expertise, driving market growth and fostering scientific advancement.

Read Also: Recombinant Antibodies Market Size to Attain USD 23.34 Bn by 2033

Recent Developments

  • In September 2022, Solid Biosciences announced its acquisition of AavantiBio alongside a concurrent $75 million private placement.
  • In April 2023, Merck bolstered its immunology pipeline with the acquisition of Prometheus Biosciences, Inc.
  • In February 2023, AstraZeneca completed the acquisition of CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.
  • In August 2023, Biocytogen established two business divisions to distinguish preclinical models and Services (BioMice) from antibody-drug R&D.

Competitive Landscape

The competitive landscape of the animal model market is characterized by the presence of a diverse array of players, including academic institutions, contract research organizations (CROs), biotechnology companies, pharmaceutical companies, and vendors of animal models and research reagents. Academic institutions play a significant role in animal modeling research, contributing to the development of novel animal models and conducting preclinical studies to elucidate disease mechanisms and evaluate therapeutic interventions. Contract research organizations (CROs) provide specialized services in animal model generation, preclinical testing, and drug development, catering to the needs of pharmaceutical and biotechnology companies seeking to outsource preclinical research activities.

Biotechnology companies and pharmaceutical companies are actively engaged in animal modeling research to support drug discovery and development efforts. These companies utilize animal models to validate drug targets, assess drug efficacy and safety profiles, and evaluate potential therapeutic interventions across a wide range of therapeutic areas. Moreover, vendors of animal models and research reagents supply a variety of research organisms, including mice, rats, zebrafish, and non-human primates, as well as specialized reagents and tools for animal model research. These vendors compete based on product quality, reliability, pricing, and customer support services.

Animal Model Market Companies

  • Charles River Laboratories
  • The Jackson Laboratory
  • genOway
  • Taconic Biosciences, Inc.
  • Janvier Labs
  • Harbour BioMed
  • Crown Bioscience
  • Inotiv
  • BioSpherix, Ltd.

Segments Covered in the Report

By Application

  • Cancer
  • Immunological Disease
  • Infectious Disease
  • Others

By Animal Type

  • Mice
  • Rat
  • Guinea Pigs
  • Rabbits
  • Hamsters
  • Others

By End-use

  • Pharmaceutical & Biotechnology Companies
  • Academic Research Institute
  • Contract Research Organization

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333







Leave a Reply

Your email address will not be published. Required fields are marked *